All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
Clinical trial NCT05345002 · RECRUITING
Trial details
- NCT number
- NCT05345002
- Sponsor
- Stephen Bagley, MD, MSCE
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-16
- Primary completion
- 2027-06-01
- Enrollment
- 55
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.